Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting.

Biswas S, Dodwadkar NS, Sawant RR, Koshkaryev A, Torchilin VP.

J Drug Target. 2011 Aug;19(7):552-61. doi: 10.3109/1061186X.2010.536983. Epub 2011 Feb 25.

2.

Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.

Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP.

J Control Release. 2012 May 10;159(3):393-402. doi: 10.1016/j.jconrel.2012.01.009. Epub 2012 Jan 20.

3.

Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.

Biswas S, Dodwadkar NS, Deshpande PP, Parab S, Torchilin VP.

Eur J Pharm Biopharm. 2013 Aug;84(3):517-25. doi: 10.1016/j.ejpb.2012.12.021. Epub 2013 Jan 17.

4.

Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.

Koshkaryev A, Thekkedath R, Pagano C, Meerovich I, Torchilin VP.

J Drug Target. 2011 Sep;19(8):606-14. doi: 10.3109/1061186X.2010.550921. Epub 2011 Jan 29.

5.

Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.

Kuai R, Yuan W, Qin Y, Chen H, Tang J, Yuan M, Zhang Z, He Q.

Mol Pharm. 2010 Oct 4;7(5):1816-26. doi: 10.1021/mp100171c. Epub 2010 Aug 11.

PMID:
20701288
6.

The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.

Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL.

Biomaterials. 2011 Aug;32(24):5673-87. doi: 10.1016/j.biomaterials.2011.04.029. Epub 2011 May 7.

PMID:
21550109
7.

Screening and optimization of ligand conjugates for lysosomal targeting.

Meerovich I, Koshkaryev A, Thekkedath R, Torchilin VP.

Bioconjug Chem. 2011 Nov 16;22(11):2271-82. doi: 10.1021/bc200336j. Epub 2011 Oct 6.

8.

Detection of de- and hyperpolarization of mitochondria of cultured astrocytes and neurons by the cationic fluorescent dye rhodamine 123.

Kahlert S, Zündorf G, Reiser G.

J Neurosci Methods. 2008 Jun 15;171(1):87-92. doi: 10.1016/j.jneumeth.2008.02.015. Epub 2008 Mar 6.

PMID:
18400303
9.

Folate receptor-targeted fluorescent paramagnetic bimodal liposomes for tumor imaging.

Ding N, Lu Y, Lee RJ, Yang C, Huang L, Liu J, Xiang G.

Int J Nanomedicine. 2011;6:2513-20. doi: 10.2147/IJN.S23934. Epub 2011 Oct 20.

10.

Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.

Hadinoto K, Sundaresan A, Cheow WS.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17. Review.

PMID:
23872180
11.
12.

Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.

He X, Li L, Su H, Zhou D, Song H, Wang L, Jiang X.

Int J Nanomedicine. 2015 Mar 5;10:1791-804. doi: 10.2147/IJN.S75186. eCollection 2015.

13.

Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.

Vaidya B, Vyas SP.

J Drug Target. 2012 May;20(4):372-80. doi: 10.3109/1061186X.2012.662687. Epub 2012 Feb 18.

PMID:
22339366
14.

Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.

Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC.

Int J Pharm. 2009 Dec 1;382(1-2):254-61. doi: 10.1016/j.ijpharm.2009.08.002. Epub 2009 Aug 8.

PMID:
19666094
15.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
16.

Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers.

Salmaso S, Pappalardo JS, Sawant RR, Musacchio T, Rockwell K, Caliceti P, Torchilin VP.

Bioconjug Chem. 2009 Dec;20(12):2348-55. doi: 10.1021/bc900369d.

PMID:
19928843
17.

Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.

Jiang L, Li L, He X, Yi Q, He B, Cao J, Pan W, Gu Z.

Biomaterials. 2015 Jun;52:126-39. doi: 10.1016/j.biomaterials.2015.02.004. Epub 2015 Feb 24.

PMID:
25818419
18.
19.

Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.

Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A.

Br J Cancer. 1996 Dec;74(11):1749-56.

20.

The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.

Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, Sun MG, Shi JF, Zhang CX, Lu WL.

Biomaterials. 2013 May;34(14):3626-38. doi: 10.1016/j.biomaterials.2013.01.078. Epub 2013 Feb 16.

PMID:
23422592

Supplemental Content

Support Center